The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
Anastasios Stathis
No relevant relationships to disclose
Kami J. Maddocks
No relevant relationships to disclose
Ian Flinn
Research Funding - Immunogen
Alex Mejia
No relevant relationships to disclose
Maria Lia Palomba
No relevant relationships to disclose
Sybil Zildjian
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Mary Murphy
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Jutta Deckert
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Rodrigo Ruiz-Soto
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Arnold Freedman
No relevant relationships to disclose